


Nigeria

Region: West Africa

Key information on co-financing

- Gross National Income per capita (2017): \$ 2,080
- Co-financing status (2019): Accelerated transition phase
- Gavi Board has approved the extension of transition period for Nigeria until 2028.




Immunisation financing

	2013	2014	2015	2016	2017
Vaccines used in routine immunisation					
- Government expenditure	\$ 40,629,508	\$ 37,227,051	\$ 118,997,375	\$ 120,000,000	\$ 35,480,412
- Total expenditure	\$ 73,764,508	\$ 90,962,051	\$ 238,997,375	\$ 422,000,000	\$ 254,161,590
- Government as % of total	55%	41%	50%	28%	14%
Routine immunisation					
- Government expenditure	\$ -	\$ 49,205,698	\$ 120,829,723	\$ 185,000,000	\$ 78,145,947
- Total expenditure	\$ -	\$ 204,675,066	\$ 302,100,133	\$ 639,150,767	\$ 321,615,273
- Government as % of total	N/A	24%	40%	29%	24%

Source: WHO-UNICEF Joint Reporting Form 2017

Domestic General government expenditure on health as a share of gross domestic product: **27%**

Expenditure on routine immunisation in 2017



Source: WHO National Health Accounts, 2015

Gavi supported vaccines

Vaccines	Type	Year(s) of Gavi support	Co-financing required
Yellow Fever	Routine	2007-2013	Fully self-financing
Meningitis A	Campaign	2011-2014	No
Pentavalent	Routine	2012-present	Yes
Measles SIA	Campaign	2013, 2015, 2018	No
Yellow Fever	Campaign	2013, 2016, 2018	No
PCV	Routine	2014-present	Yes
IPV	Routine	2014-present	No

Co-financing payments

Year	Total amount paid by the country	Co-financed vaccines		
		Vaccine	Year	Amount
2011	\$ 730,000	-	Yellow Fever	-
2012	\$ 5,919,000	Penta	Yellow Fever	-
2013	\$ 18,070,000	Penta	Yellow Fever	-
2014	\$ 8,489,000	Penta	Yellow Fever	PCV
2015	\$ 16,140,000	Penta	Yellow Fever	PCV
2016	\$ 29,269,000	Penta	*	PCV
2017	\$ 38,101,000	Penta	*	PCV
2018	\$ 21,908,000	Penta	*	PCV


* Nigeria is fully self-financing Yellow Fever as of 2014.

Co-financing obligations for 2019

	Co-financing obligations (in US\$)	Co-financing obligations (in doses)
PCV	\$ 15,065,500	4,853,200
MenA	\$ 1,253,000	2,122,000
Pentavalent	\$ 4,521,500	5,976,000
Measles	\$ 408,000	1,234,700
Measles follow up campaign	\$ 3,144,500	8,150,800
Total	\$ 24,392,500	

Note: Country revised the requirement for Pentavalent volume in February 2019.

Co-financing projections for 2020 - 2024



	2020	2021	2022	2023	2024
MenA Routine	\$ 1,023,849	\$ 1,463,893	\$ 2,248,740	\$ 3,100,159	\$ 4,253,410
Penta	\$ 10,574,544	\$ 11,995,895	\$ 13,644,873	\$ 15,012,558	\$ 16,563,138
PCV	\$ 24,876,361	\$ 29,546,615	\$ 35,040,402	\$ 40,050,400	\$ 45,759,579
HPV national	\$ -	\$ -	\$ -	\$ 1,821,750	\$ 2,359,582
YF routine (fully self-financed)	\$ 4,254,275	\$ 4,863,189	\$ 5,820,660	\$ 6,473,400	\$ 7,372,984
Rota	\$ 598,200	\$ 2,806,822	\$ 4,946,084	\$ 8,048,207	\$ 9,245,020
Total	\$ 41,327,229	\$ 50,676,414	\$ 61,700,759	\$ 74,506,473	\$ 85,553,713

- Projections are based on Gavi's operational forecast version 16.
- These projections do not guarantee renewal of support or approval of country's application.
- Final co-financing obligations will be communicated through decision letters.